Cutaneous larva migrans requires targeted antiparasitic treatment. Current evidence-based guidelines define a clear first-line approach, with both oral and topical options available depending on the clinical situation.
First-line management is built around oral antiparasitic therapy, with a single-dose oral agent identified as the preferred choice in current guidelines. Alternative regimens — including topical formulations — are also part of the structured protocol.
DOI: 10.1111/ddg.15611
According to the German S1-guideline, a single dose of oral ivermectin 200 μg per kg body weight (BW) is the treatment of choice.
Alternatively, oral albendazole 800 mg per day for 3 days or topical albendazole 10% three times per day for 7–10 days is recommended.
View source ↗